The iRelate is a PET imaging trial to compare two upcoming and promising T cell PET tracers. Following chemo-immuno therapy, as part of standard care, NSCLC patients will be recruited to receive two PET scans, shortly before their surgery. Both PET scans will be compared to each other, as well as compared to the pathological analysis of the resected tumor.
This study will provide detailed information on the unique as well as additive capacities of imaging biomarkers derived from the immune cell targeting PET tracers.
Histologically confirmed NSCLC
T1-4N0-2, lesion size of ≥2cm, at time of the restaging FDG PET/CT
Planned to undergo resection after chemo-IO according to routine treatment guidelines
Willing and able to provide written informed consent for the trial
Patients deemed inoperable
Patients who have received a splenectomy
Patients who have received any vaccination within 14 days of enrollment
Patients with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of day 0. Inhaled or topical steroids, and adrenal replacement steroid >10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
Amsterdam UMC, location VUmc
Lead sponsor
Foundation for the National Institutes of Health
Collaborator